Patients who received Abbott Laboratories’ novel dissolving vascular stent had a significantly higher rate of serious adverse heart events than those treated with the company’s widely used Xience drug-coated metal stent two years after implantation, according to data presented on Saturday.
New guidelines for blood vessel size and proper implantation techniques put in place for the new Absorb stent since the study began, however, should lead to better results, researchers said.
